Chemical Exchange Saturation Transfer (CEST) MRI for the Characterization Small Renal Masses

用于表征小肾脏肿块的化学交换饱和转移 (CEST) MRI

• 批准号: 10406271
• 负责人: IVAN E DIMITROV
• 金额: $ 41.36万
• 依托单位: UT SOUTHWESTERN MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-05-17 至 2026-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10406271
• 关键词: Abdomen; Ablation; Academia; Acceleration; Accounting; Address; Adopted; Algorithms; Benign; Biological Markers; Biopsy; Chemicals; Clear cell renal cell carcinoma; Clinical; Clinical Assessment Tool; Clinical Research; Collaborations; Complication; Contrast Media; Deposition; Detection; Development; Diagnosis; Early Diagnosis; Elements; Evaluation; Exposure to; Fatty acid glycerol esters; Glycogen; Goals; Histologic; Histology; Histopathology; Human; Image; Imaging Device; Imaging technology; Immunohistochemistry; Incidence; Indolent; Industry; Injections; Kidney; Knowledge; Magnetic Resonance Imaging; Malignant - descriptor; Malignant Neoplasms; Maps; Measurement; Medical center; Metabolic; Methodology; Methods; Molecular; Morbidity - disease rate; Motion; North America; Oncology; Operative Surgical Procedures; Oxyphilic Adenoma; Patient-Focused Outcomes; Patients; Perfusion; Predictive Value; Procedures; Prognosis; Protocols documentation; Publications; Renal Cell Carcinoma; Renal Mass; Renal carcinoma; Reporting; Research; Research Personnel; Resolution; Role; Scientist; Signal Transduction; Specialized Program of Research Excellence; Spectrum Analysis; Stratification; Structure; Techniques; Technology; Technology Transfer; Texas; Tissues; Translating; Translations; Universities; Woman; anatomic imaging; base; breast lesion; clinical center; clinical translation; cohort; imaging modality; imaging system; improved; in vivo; industry partner; kidney imaging; men; mortality; neuro-oncology; non-invasive imaging; novel; overtreatment; preclinical study; predictive marker; programs; psychologic; recruit; respiratory; risk stratification; soft tissue; success; tool; tumor; tumor microenvironment; virtual biopsy

Project Summary An Academic-Industrial partnership between scientists and clinicians at the University of Texas Southwestern (UTSW) Medical Center and Philips Research Hamburg and Philips North America (Philips) has been formed with the purpose of translating the novel molecular MR imaging method, Chemical Exchange Saturation Transfer (CEST), into a clinical tool for the assessment of Small Renal Masses (SRMs). CEST has already demonstrated feasibility in neurooncology applications. The management of SRMs is challenging because a substantial number of them are benign or indolent malignant tumors, leading to patient exposure to unnecessary morbidity from biopsies and surgery. Non-invasive distinction between benign/indolent tumors and aggressive tumors would allow for better risk stratification and patient management. While novel, CEST has already been adopted by certain clinical centers for assessment in neuro oncology. Recently, our group demonstrated the promise of CEST to the characterization of breast lesions. Here, we propose to broaden the application of CEST to renal oncology by addressing the inherent challenges of application of CEST in the abdomen and by optimizing CEST in patients with SRMs. Our hypothesis is that technical development of CEST-MRI allows observation of aggressive tumor microenvironment in SRM. Our goal is to advance CEST methodology to become a part of comprehensive SRM evaluation protocol. The goals of the project will be achieved via the following Specific Aims: Aim 1: To develop and optimize CEST methodology for SRMs on 3T human MRI system. This is technical development Aim, where we will evaluate several approaches addressing major issues associated with translation of CEST to kidney oncology applications: (i) improved resolution and fat separation, (ii) acceleration of acquisition using pseudo-cartesian and undersampled algorithms,(iii) motion correction and (iv) advanced Z-spectrum analysis methods. Aim 2: To evaluate the optimized CEST-MRI as a predictive biomarker of SRM hystology. The Aim's focus in on the translation of the CEST technology to SRM patients: (i) evaluation of the optimized in a group of SRM patients: (ii) correlation of the CEST-MRI measurements with histopathology results and correlation of CEST-MRI with glycogen deposition.

项目概要 德克萨斯大学西南分校科学家和临床医生之间的学术与工业合作伙伴关系 (UTSW) 医疗中心和飞利浦汉堡研究中心和飞利浦北美公司 (Philips) 已成立 目的是转化新型分子磁共振成像方法“化学交换饱和度” 将 (CEST) 转移到用于评估小肾脏肿块 (SRM) 的临床工具中。中欧夏令时已经 证明了在神经肿瘤学应用中的可行性。 SRM 的管理具有挑战性，因为 其中相当一部分是良性或惰性恶性肿瘤，导致患者暴露于 活检和手术造成不必要的发病率。良性/惰性肿瘤的非侵入性区分 侵袭性肿瘤将有助于更好的风险分层和患者管理。虽然新颖，但 CEST 已被某些临床中心采用用于神经肿瘤学评估。最近，我们组 证明了 CEST 在描述乳腺病变特征方面的前景。在此，我们建议扩大 通过解决 CEST 在肾肿瘤学中应用的固有挑战，将 CEST 应用于肾肿瘤学 腹部并通过优化 SRM 患者的 CEST。 我们的假设是，CEST-MRI 的技术发展可以观察侵袭性肿瘤 SRM 中的微环境。我们的目标是推进 CEST 方法，使其成为综合 SRM 的一部分 评估协议。该项目的目标将通过以下具体目标来实现： 目标 1：开发和优化 3T 人体 MRI 系统上 SRM 的 CEST 方法。 这是技术开发目标，我们将评估解决主要问题的几种方法 与 CEST 转化为肾脏肿瘤学应用相关：(i) 提高分辨率和脂肪分离， (ii) 使用伪笛卡尔和欠采样算法加速采集，(iii) 运动校正和 (iv) 先进的 Z 谱分析方法。 目标 2：评估优化的 CEST-MRI 作为 SRM 组织学的预测生物标志物。 该目标的重点是将 CEST 技术转化为 SRM 患者：(i) 评估优化方案 在一组 SRM 患者中：(ii) CEST-MRI 测量值与组织病理学结果的相关性以及 CEST-MRI 与糖原沉积的相关性。